The Alzheimer's Disease Research Center at the University of California, Irvine

加州大学欧文分校阿尔茨海默病研究中心

• 批准号: 9922099
• 负责人: FRANK M LAFERLA
• 金额: $ 288.37万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-15 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9922099
• 关键词: Address; Adult; Advisory Committees; Age; Aged, 80 and over; Alleles; Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer' s disease risk; Alzheimer' s disease therapy; Asian Americans; Autopsy; Basic Science; Biological Markers; Blood; Brain Diseases; Brain Pathology; California; Clinical; Clinical Research; Clinical Sciences; Clustered Regularly Interspaced Short Palindromic Repeats; Cognitive; Communities; Complex; Computer software; Consent; County; Data; Data Analyses; Data Set; Dementia; Development; Diagnosis; Dimensions; Disease; Down Syndrome; Education; Ensure; Epidemic; Ethics; Ethnic group; Etiology; Faculty; Genetic; Goals; Image; Impaired cognition; Individual; Infrastructure; International; Knowledge; Leadership; Longevity; Mission; Modernization; Molecular; Nature; Older Population; Oranges; Outcome; Participant; Pathogenesis; Pathologic; Pathway interactions; Patients; Play; Populations at Risk; Predisposition; Productivity; Protocols documentation; Recording of previous events; Registries; Research; Research Methodology; Research Personnel; Resources; Role; Scholarship; Science; Scientist; Societies; Stains; Sum; Technology; Training; Translational Research; Universities; Vision; Work; aging population; biomarker development; brain tissue; cell bank; cohort; data management; data resource; education research; effective therapy; in vivo; induced pluripotent stem cell; innovation; insight; interdisciplinary approach; interdisciplinary collaboration; meetings; mild cognitive impairment; multidisciplinary; named group; neuroimaging; neuroimaging marker; neuropathology; next generation; novel; novel diagnostics; open source; participant retention; prevent; prodromal Alzheimer' s disease; recruit; resilience; stem cell biology; success

UCI ADRC Overall Project Summary/Abstract The central theme of the University of California, Irvine Alzheimer's Disease Research Center (UCI ADRC) is to identify, quantify, and validate factors that influence the risk of Alzheimer's disease (AD) across the lifespan. Given its diverse and multifactorial nature, it is critical to understand the etiology and progression of this insidious brain disorder at multiple dimensions, including clinically and neuropathologically, and to employ novel scientific approaches so that we can advance knowledge and better diagnose, prevent and cure the disease. The UCI ADRC has a strong history of integrating basic, clinical, and translational science to gain insights into AD pathogenesis and to help meet some of the goals of the National Alzheimer's Project Act. First, our Center has a distinguished record of studying the disease in diverse patient cohorts: Uniform Data Set (UDS) Cohort, which includes cognitively normal individuals and individuals with mild cognitive impairment (prodromal AD); adults with Down syndrome, representing the largest genetically at-risk population for AD; and 90+, which show great disparity between AD pathology and cognitive loss and are among the oldest group of individuals to develop AD. Together, these cohorts enable interrogation of important novel questions related to age, susceptibility and resilience, using innovative outcomes ranging from in vivo biomarker characterization to modern pathological outcomes such as post-mortem imaging and microglial staining. Second, the UCI ADRC has a history of innovation that has helped advance the field; the development of the nation's first induced pluripotent stem cell bank for AD as part of the ADRC network and our recently established Consent-to- Contact recruitment registry are recent examples of this innovation. Third, our Center continues to evolve. Given the expertise, productivity, and resources devoted the study of special populations at UCI, we have initiated two Special Populations Cores, one focused on Down syndrome and one focused on the oldest old (90+). These Cores will interact with the other cores of the ADRC to produce novel data and resources available to ADRC investigators, including through our newly established Biomarker Core. Finally, we have established a new Research and Education Component in this proposal, which harnesses the long-standing passionate commitment to training the next generation of clinicians and scientists at UCI. In sum, the UCI ADRC brings energetic and innovative multi-dimensional and multidisciplinary approaches toward addressing the national epidemic of AD.

UCI ADRC总体 项目总结/摘要 加州大学欧文分校阿尔茨海默病研究中心（UCI ADRC）的中心主题是 识别、量化和验证影响整个生命周期中阿尔茨海默病（AD）风险的因素。 鉴于其多样性和多因素性，了解其病因和进展至关重要。 包括临床和神经病理学在内的多个维度的隐匿性脑部疾病，并采用 新的科学方法，使我们能够推进知识和更好地诊断，预防和治疗 疾病UCI ADRC具有整合基础，临床和转化科学的悠久历史， 深入了解AD发病机制，并帮助实现国家阿尔茨海默病项目法案的一些目标。 首先，我们的中心在研究不同患者队列中的疾病方面有着杰出的记录：统一数据 集合（UDS）队列，包括认知正常个体和轻度认知障碍个体 （前驱AD）;患有唐氏综合征的成年人，代表AD的最大遗传风险人群;以及 90岁以上，显示出AD病理学和认知丧失之间的巨大差异，是最古老的老年人群体之一。 个人发展AD。总之，这些队列能够询问与以下方面有关的重要新问题： 年龄，易感性和弹性，使用创新的结果，从体内生物标志物表征， 现代病理结果，如死后成像和小胶质细胞染色。第二，UCI ADRC 有一个创新的历史，有助于推动该领域的发展;国家的第一个诱导的发展 作为ADRC网络的一部分，我们最近建立了AD多能干细胞库， 联系招聘登记处是这种创新的最新例子。第三，我们的中心在不断发展。 鉴于专门知识，生产力和资源投入到特殊人群的研究在UCI，我们有 启动了两个特殊人群核心，一个专注于唐氏综合症，一个专注于最年长的老年人 (90+).这些核心将与ADRC的其他核心进行交互，以产生新的数据和资源 可供ADRC研究人员使用，包括通过我们新建立的生物标志物核心。我们终于有 在这项提案中建立了一个新的研究和教育部分，利用长期存在的 热情致力于在UCI培训下一代临床医生和科学家。总之，UCI ADRC带来了充满活力和创新的多维和多学科的方法来解决 AD的全国流行。